The combination of OPC-167832 with other new or repurposed anti-TB drugs, especially the regimen comprised of OPC-167832, DMD, BDQ, and MXF, exhibited excellent outcomes in relapse prevention in a mouse TB model. This evidence concerns the gene DMD and tuberculosis.